Avidity Biosciences
Tracked across 3 events · 35 articles · First seen Sep 01, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Avidity was acquired by Novartis for about $12 billion, and the failure of del-desiran, one of its lead AOC assets, has dented confidence in the value and rationale of that acquisition.
Sep 08, 2026 · 21 articles
Business
Artisan Partners Asset Management, a top-20 shareholder in Swiss drugmaker Novartis, publicly called for a shake-up of the company's board to improve corporate governance and oversight of acquisitions. David Samra, managing director at Artisan Partners…
Impact: U.S. firm acquired by Novartis for $12 billion whose muscle-wasting disorder drug failed a late-stage study, triggering the share slump.
Sep 10, 2026 · 6 articles
Business
Impact: Avidity Biosciences is mentioned as Davé's previous employer, providing context for his experience. No direct impact on Avidity from this event.
Sep 01, 2026 · 8 articles
80
Novartis acquired Avidity BiosciencesArtisan Partners Urges...
ERGEN INTELLIGENCE
Track Avidity Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard